Chengdu Jiaozi Oriental Investment Development Partnership (Limited Partnership) completed the acquisition of 5% stake in Chengdu Huasun Technology Group Inc., Ltd. from Wang Anquan.
November 10, 2020
Share
Chengdu Jiaozi Oriental Investment Development Partnership (Limited Partnership) signed an agreement to acquire 5% stake in Chengdu Huasun Technology Group Inc., Ltd. (SZSE:000790) from Wang Anquan for approximately CNY 140 million on October 30, 2020. Chengdu Jiaozi Oriental Investment Development Partnership will acquire 30.8 million shares at a price of CNY 4.608 per share. Under the terms of the transaction, CNY 30 million will be paid within three trading days after the completion of the transfer and registration of the underlying shares and CNY 112 million will be paid within seven trading days from the date of completion of the transfer and registration of the underlying shares.
Chengdu Jiaozi Oriental Investment Development Partnership (Limited Partnership) completed the acquisition of 5% stake in Chengdu Huasun Technology Group Inc., Ltd. (SZSE:000790) from Wang Anquan on November 11, 2020.
Chengdu Huasun Technology Group Co Ltd, formerly Chengdu Taihe Health Technology Group Inc., Ltd., is principally engaged in manufacture and distribution of Chinese medicines and Western medicines, fabrication and installation services of steel structures, as well as production and sale of bio-engineering products. The Company primarily provides Chinese medicines, Western medicines, biological drugs, veterinary drugs and veterinary biological vaccines, as well as modern steel structures. Its pharmaceutical products include oral liquid, capsules, biological products and veterinary drugs, among others. The Company operates its businesses primarily in the China domestic market, with Sichuan province as its main market.
Chengdu Jiaozi Oriental Investment Development Partnership (Limited Partnership) completed the acquisition of 5% stake in Chengdu Huasun Technology Group Inc., Ltd. from Wang Anquan.